tirzepatide cvot cardiovascular event risk assessment: a pre-specified meta-analysis 🫀 EASD 2025: Tirzepatide (SURPASS-CVOT)

In the present work we provide further evidence supporting the high GLP-1R specificity of this antibody

Data from the STEP [52] and SUSTAIN [53, 54] trials consistently demonstrate that the substantial weight loss achieved with semaglutide at doses of 0.5 mg, 1.0 mg, and 2.4 mg is largely independent of these symptoms, with less than 1% of the total weight loss benefit attributable to GI AEs

Invest 116 , 24642472 (2006)

Reductions in Covid deaths among those on Wegovy also contributed to lower overall death rates in this group compared to patients on placebo, researchers said

You prefer to pick your pharmacy

Ozempic didn't increase the metabolism to burn more calories like many weight loss medications